Editorial & Opinion
Editorial: Model-informed drug development and evidence-based translational pharmacology.
| العنوان: | Editorial: Model-informed drug development and evidence-based translational pharmacology. |
|---|---|
| المؤلفون: | Zhao J; Biomedicine Discovery Institute, Infection and Immunity Program and Department of Microbiology, Monash University, Melbourne, VIC, Australia., Zhu X; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China., Tan S; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China., Chen C; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China., Kaddoumi A; Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL, United States., Guo XL; Department of Pharmacology, School of Pharmaceutical Science, Shandong University, Jinan, China., Lin YW; Biomedicine Discovery Institute, Infection and Immunity Program and Department of Microbiology, Monash University, Melbourne, VIC, Australia.; Malaya Translational and Clinical Pharmacometrics Group, Faculty of Pharmacy, University of Malaya, Kuala Lumpur, Malaysia.; Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, University of Malaya, Kuala Lumpur, Malaysia.; Integrated Drug Development, Certara, NJ, United States., Cheung SYA; Integrated Drug Development, Certara, NJ, United States. |
| المصدر: | Frontiers in pharmacology [Front Pharmacol] 2022 Dec 12; Vol. 13, pp. 1086551. Date of Electronic Publication: 2022 Dec 12 (Print Publication: 2022). |
| نوع المنشور: | Editorial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Media] |
| مستخلص: | Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| References: | Clin Pharmacol Ther. 2021 Apr;109(4):928-941. (PMID: 33565627) CPT Pharmacometrics Syst Pharmacol. 2018 Dec;7(12):785-787. (PMID: 30255663) Clin Pharmacol Ther. 2021 Jan;109(1):175-183. (PMID: 32996120) CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):777-791. (PMID: 31535440) CPT Pharmacometrics Syst Pharmacol. 2019 Feb;8(2):59-61. (PMID: 30407746) CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):413-415. (PMID: 28568566) Br J Clin Pharmacol. 2020 Feb;86(2):196-198. (PMID: 31729048) Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:225-245. (PMID: 33035445) Lancet Microbe. 2022 Oct;3(10):e795-e802. (PMID: 35777386) Pharm Res. 2022 Aug;39(8):1669-1680. (PMID: 35552984) Expert Opin Drug Discov. 2019 Jan;14(1):1-4. (PMID: 30488727) CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1127-1129. (PMID: 34404115) Mol Divers. 2021 Aug;25(3):1315-1360. (PMID: 33844136) CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1150-1160. (PMID: 34270885) Clin Pharmacol Ther. 2020 Apr;107(4):726-729. (PMID: 31925955) J Clin Pharmacol. 2008 Feb;48(2):146-56. (PMID: 18199891) Pharmacotherapy. 2021 Nov;41(11):953-963. (PMID: 34618919) Mol Divers. 2021 Aug;25(3):1517-1539. (PMID: 34282519) CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):93-122. (PMID: 27069774) J Clin Pharmacol. 2019 Sep;59 Suppl 1:S104-S111. (PMID: 31502691) OMICS. 2019 Nov;23(11):539-548. (PMID: 31651216) J Pharmacokinet Pharmacodyn. 2022 Feb;49(1):19-37. (PMID: 34671863) Drug Discov Today. 2017 Nov;22(11):1680-1685. (PMID: 28881183) Clin Pharmacol Ther. 2021 Apr;109(4):867-891. (PMID: 33555032) Front Physiol. 2021 Mar 25;12:637999. (PMID: 33841175) CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):380-395. (PMID: 31087533) CPT Pharmacometrics Syst Pharmacol. 2019 Feb;8(2):87-96. (PMID: 30411538) CPT Pharmacometrics Syst Pharmacol. 2020 Mar;9(3):129-142. (PMID: 31905263) Clin Pharmacol Ther. 2022 Mar;111(3):572-578. (PMID: 34807992) |
| فهرسة مساهمة: | Keywords: artificial intelligence; machine learing; model informed drug development; pharmacometrics; translational pharmacology |
| تواريخ الأحداث: | Date Created: 20221229 Latest Revision: 20230103 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9791580 |
| DOI: | 10.3389/fphar.2022.1086551 |
| PMID: | 36578539 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2022.1086551 |